Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
EMERYVILLE, Calif., May 1 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), today announced it has received a quarterly royalty payment of approximately $1.5 million from Merz Pharmaceuticals GmbH (Merz) for sales of Memantine for the treatment of Alzheimer's...
B. Braun Medical Inc. to Demonstrate Infusion Systems Technologies at HIMSS 2009 Interoperability Showcase
Integrated Solution's Electronic Health Record Capability Highlighted
BETHLEHEM, Pa., March 31 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun) said its Outlook(R) Safety Infusion System , DoseTrac(TM) Infusion Management Software and DoseLink(TM) Interfaces successfully completed ...
MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
WOONSOCKET, R.I., March 19 /PRNewswire-FirstCall/ --MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) announced today that it has entered into a cooperative research and development agreement with Maxim Biotech, Inc. to develop products for the study of liver stem cells and liver cancer.
Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
Varian to showcase products ranging from treatment planning software for radiation therapy to flat panel detectors for filmless X-ray imaging
BEIJING, March 16 /PRNewswire-FirstCall/ -- Varian Medical Systems, Inc. (NYSE: VAR ) will showcase the full spectrum of the company's cancer treatme...
BioSpecifics Technologies Corp. to Present at Cowen and Company 29th Annual Health Care Conference
LYNBROOK, N.Y., March 10 /PRNewswire-FirstCall/ -- BioSpecifics Technologies
Corp. (Nasdaq: BSTC ), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming Cowen ...
Neuro Kinetics: Research Suggests I-Portal(R) NOTC Data Shows Mild Traumatic Brain Injuries That Other Technologies Miss
Unique Case Study of Patient Before & After mTBI Accident
Presentation at American Balance Society, Case Study on Web Site, New Help for Returning Vets
PITTSBURGH, March 4 /PRNewswire/ -- With record numbers of American soldiers returning from Iraq and Afghanistan with brain injuries...
Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
EMERYVILLE, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Neurobiological
Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) today announced that an independent
Data Safety Monitoring Board (DSMB) has determined that the current clinical
trials of Viprinex(TM) for the treatment of acute ischemic stroke are...
InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
BILTHOVEN and AMSTERDAM, The Netherlands, October 30 /PRNewswire/ --
B.V. and VU university medical center in Amsterdam,
VUmc, announce today the signing of a framework research agreement to
develop microRNA (miRNA)-based diagnostics and therapeutics for cancer
Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
- Company Plans to Announce Interim Results in January 2009 and Final Trial Data in mid-2009 -
EMERYVILLE, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Neurobiological
Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) today announced that following a
meeting with the U.S. Food ...
Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
BOSTON, Sept. 24 /PRNewswire-FirstCall/ -- Cancer treatment specialists
reported yesterday how new technologies
are enabling them to provide
faster, more accurate cancer treatments than was possible with earlier
generations of radiotherapy technology. In presentations given at an
Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
CRANBURY, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Palatin
Technologies, Inc. (Amex: PTN ) announced it presented results from a Phase
1 clinical study with PL-3994, a novel, long-acting natriuretic peptide
receptor A (NPRA) agonist under development for treatment of the chronic
treatment of ...
BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronie's Disease
LYNBROOK, N.Y. Sept. 17 /PRNewswire-FirstCall/ -- BioSpecifics
Technologies Corp. (OTC Bulletin Board: BSTC), a biopharmaceutical company
developing first in class collagenase based products, announced today the
initiation of a U.S. Phase IIb clinical trial in Peyronie's disease for its
Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
EMERYVILLE, Calif., Aug. 12 /PRNewswire-FirstCall/ -- Neurobiological
Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) today announced that enrollment
into its two Phase 3 pivotal studies evaluating Viprinex(TM) (ancrod) for
the treatment of acute ischemic stroke has reached the level of patients
New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times
First Patients Treated Using Next Generation CyberKnife System at Oklahoma CyberKnife Center
SUNNYVALE, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Accuray
Incorporated (Nasdaq: ARAY ), a global leader in the field of radiosurgery,
announced today that the first patients...
MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
MONMOUTH JUNCTION, N.J., Aug. 5 /PRNewswire/ -- MicroDose Technologies
Inc. (MicroDose) today announced that the first clinical milestone in its
collaboration with Merck & Co., Inc., through a Merck affiliate, has been
achieved, triggering the first payment under the global license agreement
Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH)
Phase I Study to Explore the Effects of Eligen(R) Delivery Technology on Healthy Postmenopausal Women
CEDAR KNOLLS, N.J., June 30 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS ) announced today that Novartis Pharma AG
has launched a Phase I study in...
Duke Licenses ALPHADAS(R), Logos Technologies EDC System to Accelerate its Early Phase Clinical Trials
LONDON, June 26 /PRNewswire/ -- Duke University Medical Center has
licensed ALPHADAS(R) Logos Technologies
electronic data capture (EDC)
software to accelerate and streamline its early-phase clinical trials and
to enable physicians to follow patients more closely.
Researchers at Duke, which ...
Disc Motion Technologies Announces First Human Implants of True TSMS(TM) Device
ANKARA, Turkey, June 13 /PRNewswire/ -- Disc Motion Technologies
announced the completion of the first surgical procedure to implant the
True Total Spinal Motion Segment System (TM) (TSMS(TM)), the first total
joint replacement system for the lumbar spine, featuring an artificial
lumbar disc a...
Sahajanand Medical Technologies PAINT Trial Results Support Safety and Efficacy of the Infinnium and Supralimus Stents
Sahajanand Medical Technologies
received positive results of nine month
PAINT trials for Drug eluting stents, Infinnium and Supralimus. The results unveiled during plenary session of EuroPCR 2008-Barcelona.
SURAT, India, May 20 /PRNewswire/ -- Sahajanand Medical Technologies
Pvt. Ltd. (S...
Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
CRANBURY, N.J., May 20 /PRNewswire-FirstCall/ -- Palatin Technologies,
Inc. (Amex: PTN ) announced today that dosing has been initiated in a Phase
2a clinical study of PL-3994, a novel, long-acting natriuretic peptide
receptor A agonist, in subjects with controlled hypertension.
The study i...
CoreSpine Technologies Expands Spinal Disc Site Preparation Efforts
Emerging spinal company continues to focus on unmet needs of the lumbar disc
MINNEAPOLIS, May 1 /PRNewswire/ -- CoreSpine Technologies, LLC, an
emerging spinal device company announced today the expansion of its
platform technology for spinal implant procedures...
Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology
CEDAR KNOLLS, N.J., Feb. 7 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS ) announced today that recent animal
studies have demonstrated proof of concept that absorption of oral vitamin
B12 using the company's proprietary eligen(R) technology was 15-30 times
TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
New AcuCare Programs Automate the Interface between Health Assessments for Patients and the Generation of Customized Care Treatment Plans
AUBURN, Calif., Jan. 22 /PRNewswire/ -- TCS Healthcare Technologies, an
industry leader in the development of medical management software
Senesco Technologies Initiates Preclinical Studies for Cancer Target
NEW BRUNSWICK, N.J., Dec. 5 /PRNewswire-FirstCall/ -- Senesco
Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT ) announced
today, that it has initiated preclinical lab studies at Mayo Clinic focused
on multiple myeloma. These studies will further test the ability of
King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
CRANBURY, N.J. and BRISTOL, Tenn., Aug. 30 /PRNewswire-FirstCall/ --
Palatin Technologies, Inc. (Amex: PTN ) and King Pharmaceuticals, Inc.
(NYSE: KG ) announced today that they have delayed plans for the initiation
of Phase 3 clinical trials with bremelanotide, a first in class
Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
Olympus Corporation to Support the Joint Program through the Provision of Novel Imaging Systems
Collaboration Will Bring Innovative Fluorescent Imaging Agent and System Technologies
into Clinical Trials in Ovarian Cancer
PHILADELPHIA, TOKYO and WOBURN, Mass, J...
AVAX Technologies Presents Results of Phase I-II M-Vax Trial at
Annual Meeting of American Association for Cancer Research
PHILADELPHIA--(BUSINESS WIRE)--Apr 16, 2007 - AVAX Technologies,
Inc. (OTCMarket:AVXT.OB) today announces that it is presenting the
initial results of its Phase I-II trial of M-Vax(TM) for patients
with metastatic melanoma at a Clinical Research session of the
meeting of the American Association fo...
OncoGenex Technologies Announces Phase II Data of OGX-011 in
Metastatic Breast Cancer at American Association for Cancer
Research 2007 Annual Meeting
VANCOUVER, April 17, 2007 /PRNewswire/ - OncoGenex Technologies
Inc. announced today data from a Phase II clinical trial of OGX-011
in combination with docetaxel in patients with metastatic breast
cancer (MBC). Data was presented by the National Cancer Institute
of Canada - Clinical Trials Group a...
Micell Technologies Presents Data on Novel Drug-Eluting Stents
RALEIGH, N.C., April 18, 2007 /PRNewswire/ -- Micell
Technologies announced today that the Company will be presenting
data on use of its supercritical fluid (SCF) surface modification
technology for drug-eluting stents at the upcoming Society for
Biomaterials 2007 Annual Meeting, April 19-21 2007 ...
Genelabs Technologies Announces Presentation of Data on
Non-Nucleoside HCV Polymerase Inhibitor at 20th International
Conference on Antiviral Research Meeting
REDWOOD CITY, Calif., May 02, 2007 /PRNewswire-FirstCall/ --
Genelabs Technologies, Inc. announced today that a presentation was
made today at the 20th International Conference on Antiviral
Research being held in Palm Springs, California, on a
non-nucleoside hepatitis C virus (HCV) polymerase inhi...
Palatin Technologies and King Pharmaceuticals Announce Plan To
Present Results of Bremelanotide Phase 2b Studies in Men With
CRANBURY, N.J. and BRISTOL, Tenn., May 09, 2007
/PRNewswire-FirstCall/ -- Palatin Technologies, Inc. and King
Pharmaceuticals, Inc. today announced plans to present the results
from two bremelanotide Phase 2b studies of men with erectile
dysfunction (ED). The presenters are Jed Kaminetsky, MD, Cli...
Palatin Technologies and King Pharmaceuticals Report Data Showing
Improvements in Sexual Relationship and Self-Esteem in Patients
with Erectile Dysfunction Treated with Bremelanotide
CRANBURY, N.J., and BRISTOL, Tenn., May 22, 2007
/PRNewswire-FirstCall/ -- Palatin Technologies, Inc. and King
Pharmaceuticals, Inc. reported today that data from Study 16 and
Study 17 of the Phase 2B clinical trial program evaluating
bremelanotide in men with erectile dysfunction (ED) were presen...
Neose Technologies to Present at C.E. Unterberg, Towbin Emerging
Growth Opportunities Conference
HORSHAM, Pa.--(BUSINESS WIRE)--Jul 9, 2007 - Neose Technologies,
Inc. (NasdaqGM:NTEC) announced today that it will present at the
C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
held at the Mandarin Oriental Hotel in New York City from July
10-12, 2007. The Company's presentation is...
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
Isis benefits from its partners as they advance RNA-based technologies
and develop drugs that incorporate Isis' technology resulting in financial ...d subsidiary, and the therapeutic and commercial potential of the Company's technologies
and products in development. Any statement describing Isis' goals, expecta...
Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
...on, its mission is to develop and apply innovative technologies
to the discovery of new biologic processes and new...n develops and applies integrated state-of-the-art technologies
in chemistry, biology, automation, and information...nd metabolic as well as infectious disease. These technologies
cut across the life sciences, and include genomics...
DNA Helps Reunite Children With Their Families
... industry through a $500,000 grant from The Life technologies
Foundation to develop the DNA-PROKIDS Project ...er has been responsible for the development of DNA technologies
and systems for parentage testing, forensic testin...o http://www.hsc.unt.edu/
About Life technologies
Study Shows Brain Fitness can Save Medicare Billions
...omputer-based programs. More than 30 articles in leading science and medical journals show that in randomized controlled trials the company's patented technologies
significantly increase processing speed, improve memory and attention and enhance quality of life. Posit Science has received grants from the National...
CTMM Becomes One of the World's Largest Public-Private Partnerships in Translational Medical Research
CTMM (Center for Translational Molecular Medicine) is a Netherlands-based
public-private partnership dedicated to the development of technologies
molecular medicine that enable early diagnosis and personalised treatment for
oncology, cardiovascular, neurodegenerative and infectious/auto-immun...
Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
About NanoCrystal ((R)) Technology and Elan Drug technologies
INVEGA(R) SUSTENNA(TM) utilizes the NanoCrystal((R)) Technology, which is a proprietary technology developed by Elan Drug technologies
through Elan Pharma International Limited and other Elan affiliates. NanoCr...
Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
...g of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies
including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vi...